Metagenomi Therapeutics (MGX) Cash from Investing Activities (2023 - 2025)

Metagenomi (MGX) has disclosed Cash from Investing Activities for 3 consecutive years, with $32.4 million as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities rose 13.39% to $32.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $103.5 million through Dec 2025, up 217.44% year-over-year, with the annual reading at $103.5 million for FY2025, 217.44% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was $32.4 million at Metagenomi, up from $27.4 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $75.9 million in Q3 2023, with the low at -$94.7 million in Q1 2024.
  • Average Cash from Investing Activities over 3 years is $5.1 million, with a median of $21.9 million recorded in 2025.
  • The sharpest move saw Cash from Investing Activities crashed 111.77% in 2024, then skyrocketed 406.28% in 2025.
  • Over 3 years, Cash from Investing Activities stood at $60.6 million in 2023, then tumbled by 52.92% to $28.5 million in 2024, then grew by 13.39% to $32.4 million in 2025.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at $32.4 million, $27.4 million, and $19.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.